Top Bar
 Pharma Force International






 

News & EVENTS



Recent Press Releases

Archived Press Releases

2013

“Managed Markets Structures and Strategies: Leading Pharmaceutical Companies’ Approaches” immediately available from PharmaForce International
Release Date: 7/15/2013

“Managed Markets Structures and Strategies: Leading Pharmaceutical Companies’ Approaches” immediately available from PharmaForce International

 

Firmly grounded in primary research capabilities, PharmaForce International is the recognized leader in delivering high-quality, insightful intelligence and benchmarking services.  The research conducted by PharmaForce professionals provides insights and value far beyond the typical offerings, which tend to rely solely on secondary research.  Many key insights in the report are a result of in-depth conversations with knowledgeable company personnel.

 

The Executive Summary for “Managed Markets Structures and Strategies: Leading Pharmaceutical Companies’ Approaches” concentrates on extracting meaningful observations from the companies studied for efforts in three specific areas:

      Quality Initiatives at Integrated Delivery Networks

      Field-Based Health Economics Outcomes Research

      Emerging Managed Care Models

      Patient-Centered Medical Homes

      Accountable Care Organizations

In the report, a page entitledKey Changes Since the 2012 Report” begins the section for all profiled companies.  This study guarantees that you receive unparalleled details and strategic insights as to how many companies are:

·         Providing quality improvement solutions to help customers gain better outcomes for patients

·         Deploying resources to manage relationships with specialty pharmacy channels

·         Leveraging care management programs with payers

·         Developing health outcomes approaches to payers

The balance of each company section identifies relevant and strategic developments along with up-to-date information on:

·         Strategic overview for each company

·         Deployment of key Managed Markets personnel

·         Organizational structure/reporting relationships

·         Portfolio management

·         Role of Payer Medical Liaisons

·         Role of Health Outcomes personnel

·         Role of Reimbursement personnel

·         Compensation plans for field-based employees

Upon request, PharmaForce International will send a sample company report from the “Managed Markets Structures and Strategies: Leading Pharmaceutical Companies’ Approaches” to prospective clients.

 

PharmaForce International produces custom reports at client request as well as additional syndicated studies, including:

 

  • The online and constantly refreshed “Deployment Analyzer”, which contains complete up-to-date information on sales force sizes, product priorities and compensation for sales representatives at over 60 companies in the United States and 25 companies each in Japan and in Europe. For a demo, go to www.deploymentanalyzer.com and click on the Demo Login button
  • “12th Annual Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations in the United States”
  • “Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States ”
  • Competitive Benchmarking of Six Leading Pharmaceutical Companies’ Strategies for Leveraging Health Economics Outcomes Research (HEOR) Capabilities in the United States”
  • “Integrated Delivery Networks (IDNs): Analysis of Leading Pharmaceutical Companies”

 

For more information, contact Allison Becker, Senior Director, Marketing/Operations

610-370-5640 or abecker@strategicreports.com

 

 

Top of page

'

13th Annual Benchmarking Report on the Medical Science Liaison Function immediately available from PharmaForce International
Release Date: 7/10/2013

13th Annual Benchmarking Report on the Medical Science Liaison Function immediately available from PharmaForce International

 

Prior to beginning the research process for this Medical Science Liaison best practices report, PharmaForce International conducted detailed interviews with Medical Affairs leadership to understand the most critical issues facing them in 2013. In response to this market research feedback, the report provides up-to-date and in-depth company-specific analysis on how targeted companies are adapting to respond to these many challenges:

·         Which data points should be captured to determine and measure MSL performance?

·         Which new field medical positions have been created to provide better service for key customers?

·         What degree of information is shared between MSL teams and commercial channels?

·         What strategies are employed for delivering clinical/HEOR data to payer and IDN channels?

·         What technology platforms are being deployed?

The primary research conducted by PharmaForce professionals provides insights and value far beyond the typical offerings, which tend to rely solely on secondary research.  Many key insights in the report are a result of in-depth conversations with knowledgeable company personnel.  Learn which companies are:

 

  • Developing role specialization with Health Outcomes Liaisons, Payer MSLs, Liaisons calling on NPs and PAs, and Virtual Scientific Liaisons as well as those working exclusively with clinical trials
  • Deploying ‘reactive only’ vs. ‘proactive’ MSLs

 

Upon request, PharmaForce International will send a sample company report from the 13th annual update of Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function to prospective clients.

A page entitledKey Changes Since the 2012 Report” begins the section for all profiled companies. The balance of each company section identifies relevant and strategic developments along with up-to-date information on:

·         Medical liaison deployment

·         Organizational structure

·         Evaluation methods/metrics

·         Key roles and responsibilities

·         KOL identification process

·         Liaison account management

·         Qualifications by type of liaison

·         Salary and bonus levels

PharmaForce International produces custom reports at client request as well as additional syndicated studies, including:

 

  • The online and constantly refreshed “Deployment Analyzer”, which contains complete up-to-date information on sales force sizes, product priorities and compensation for sales representatives at over 60 companies in the United States and 25 companies each in Japan and in Europe. For a demo, go to www.deploymentanalyzer.com and click on the Demo Login button
  • “12th Annual Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations in the United States”
  • “Managed Markets Structures and Strategies: Leading Pharmaceutical Companies’ Approaches”
  • Competitive Benchmarking of Six Leading Pharmaceutical Companies’ Strategies for Leveraging Health Economics Outcomes Research (HEOR) Capabilities in the United States”
  • “Integrated Delivery Networks (IDNs): Analysis of Leading Pharmaceutical Companies”

 

For more information, contact Allison Becker, Senior Director, Marketing/Operations

610-370-5640 or abecker@strategicreports.com

 

 

Top of page

'

Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging Health Economics Outcomes Research (HEOR) Capabilities in the United States
Release Date: 2/11/2013

Contact:  PharmaForce International Sales:  610-370-5640 or pfi@pharmaforce.biz

A new study from PharmaForce International: “Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging Health Economics Outcomes Research (HEOR) Capabilities in the United States”

February 7, 2013. PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its newest study Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging Health Economics Outcomes Research (HEOR) Capabilities in the United States.

In this timely report, PharmaForce International benchmarks industry leaders who have rolled out successful HEOR strategies as well as companies developing and evolving their HEOR efforts. The study completely details the HEOR approach of these companies, offering in-depth information across key areas of interest, including:

·         Overall HEOR strategy and approach

·         Corporate office positions with roles and responsibilities for personnel in:

-         US Health Outcomes

-         Health Economics

-         Comparative Effectiveness Research

-         Patient Registries

-         Epidemiology

-         Statistics

·         Customer-facing positions with roles and responsibilities for personnel such as

-         Health Outcomes Liaisons

·         Organizational structure

-         Cross-group relationships/partnering

·         An examination of external partnerships

PharmaForce International also produces a wide variety of syndicated studies, including:

  • “Integrated Delivery Networks (IDNs): Analysis of Leading Pharmaceutical Companies”
  • The Deployment Analyzer, an “ever-green” online database which contains complete information on sales force sizes, product priorities and compensation for sales representatives at leading companies in the United States Europe, Japan, Latin America and India.  To view a free demonstration, go to www.deploymentanalyzer.com and click on the Demo login button
  •  “Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations in the United States, Europe, Japan and Latin America”.  New U.S. edition available April 2013
  • “Managed Markets Structures and Strategies: Leading Companies’ Approaches”
  • “Competitive Benchmarking of Leading Pharmaceuticals Companies’ Strategies for Leveraging the Medical Science Liaison Function in the United States and Europe”.

 

Contact:  PharmaForce International Sales:  610-370-5640 or pfi@pharmaforce.biz

Top of page

'

2012

PharmaForce International Expands Its Deployment Analyzer to Include India and Three Countries in Latin America
Release Date: 10/12/2012

Contact:  PharmaForce International Sales: 610-370-5640 or pfi@pharmaforce.biz

 

PharmaForce International Expands Its Deployment
Analyzer to Include India and Three Countries in Latin
America

 

For immediate releaseOctober 2012 PharmaForce International announces the expansion of its popular web-based analytical tool the Global Sales Force Deployment Analyzer with the addition of India and three major Latin America Markets – Argentina, Brazil and Mexico

 

The global “Deployment Analyzer” now information for leading pharma companies in India, Argentina, Brazil and Mexico. The addition of these markets compliment the other major markets covered that include sales force sizes, product priorities and sales representative compensation for leading companies in the U.S., Japan and 10 countries in Europe

 

“Our commitment is to continuously look for ways to improve our offerings and the decision to include these new markets was driven by customer feedback and the importance these markets hold on a global perspective.” said Angelo Cupani, Senior Director of International Operations

 

In addition to Latin America, the Deployment Analyzer site has been updated with enhanced client search and reporting capabilities as well as with sleek new graphics. Now subscribers also have the ability to group their drugs and companies of interest together for more targeted searches. This new capability allows users to select their pre-designed grouping and view search results without having to select individual drugs and companies every time the database is utilized. This allows instant brand comparisons without having to do separate searches.

 

PharmaForce International’s Deployment Analyzer is the logical alternative to any printed report which becomes outdated almost immediately after release. It continues to be a valued tool where subscribers can confidently base their decisions on data that is accurate and virtually up to the minute

 

To see a free demonstration of PharmaForce International’s Deployment Analyzer, go to www.deploymentanalyzer.com and click on the Demo login button.

 

PharmaForce International produces custom reports at client request as well as producing syndicated studies including:

 

  • Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations: Key Expenditures and Organizational Approaches in the United States, Europe, Latin America and Japan
  • Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison in the United States and Europe
  • Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Managed Markets in the United States
  • Benchmarking of Leading Hepatitis Sales and Marketing Organizations in  the United States and Europe

 

 

 

For more information, contact PharmaForce International Sales at 610-370-5640 or at pfi@pharmaforce.biz

Top of page

'

Competitive Benchmarking of Leading Hepatitis Sales and Marketing Organizations in Europe
Release Date: 10/9/2012

Contact:  PharmaForce International Sales: 610-370-5640 or pfi@pharmaforce.biz

 

PharmaForce International Announces the Debut and Immediate Availability of its “Competitive Benchmarking of Leading Hepatitis Sales and Marketing Organizations in Europe: Key Expenditures and Organizational Approaches” Report

 

For immediate release – October 2012. PharmaForce International has announced the availability of its first edition of “Competitive Benchmarking of Leading Hepatitis Sales and Marketing Organizations in Europe: Key Expenditures and Organizational Approaches” report.  This report reveals key expenditures and organizational approaches of leading Hepatitis franchises across the Big 5 European Union (EU) countries: France, Germany, Italy, Spain and the United Kingdom.

 

This report provides a detailed analysis of key Hepatitis products promotional status and the key personnel in place supporting them and also identifies strategic partnerships and current roles the companies are playing in those relationships

 

This report offers comprehensive data that includes:

 

  • Strategic overview of the targeted hepatitis franchises
  • Sales force deployment
  • Organizational charts
  • Product portfolio management
  • Number of details by brand by target physician audience
  • Call reach and frequency analysis
  • Function of Medical Liaisons
  • Field force compensation
  • Projected marketing expenditures by brand and category

These five reports --- France, Germany, Italy, Spain and the United Kingdom --- can be purchased separately, or in combination for a significant discount. Samples of company profiles are available upon request.

 

PharmaForce International also produces custom reports upon client request as well as syndicated studies, including:

 

  • Benchmarking of Leading Hepatitis C Sales and Marketing Organizations in the United States
  • The global “Deployment Analyzer” database which covers sales force sizes, product priorities and sales representative compensation for leading pharma companies in the US, Japan, India, the EU and Latin America . (To see a free demonstration, go to www.deploymentanalyzer.com and click on the Demo login button.)
  • Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations: Key Expenditure and Organizational Approaches in the United States, Europe, Latin America and Japan
  • Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States and Europe

 

For more information, contact PharmaForce International Sales at 610-370-5640 or pfi@pharmaforce.biz

Top of page

'

A New Study from PharmaForce International
Release Date: 10/9/2012

Contact:  PharmaForce International Sales:  610-370-5640 or pfi@pharmaforce.biz

 

A New Study from PharmaForce International: “Integrated Delivery Networks (IDNs): A Detailed Analysis of Leading Pharmaceutical Companies”

 

For immediate release – October 9, 2012. PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its newest report, Integrated Delivery Networks (IDNs): A Detailed Analysis of Leading Pharmaceutical Companies.   This timely and focused study provides up-to-date information on both field-based and internal positions that are solely focused on the IDN market.

               

PharmaForce International analysts have concluded that pharma companies are realizing the old door-to-door model of selling within an IDN is not only ineffective, it is unwelcome.  Our research shows that company representatives accessing the C-Suite who know their customers’ business as well as what the customer does and who seek to be true partners for quality and process improvement have proven to be highly effective.

 

Additionally, the roles of field-based and internal HEOR personnel are often central components to individual companies’ IDN strategies.  Importantly, Health Economics and Outcomes Research (HEOR) professionals dedicated to the IDN effort are profiled in the report.

 

Integrated Delivery Networks (IDNs): A Detailed Analysis of Leading Pharmaceutical Companies provides unparalleled detail on the structure, strategies and future direction of the study companies, including:

·         IDN account position defined that serves as the lead for the company

·         Field-based Medical  Affairs personnel dedicated to IDNs

·         Health Economics and Outcomes Research (HEOR) personnel dedicated to IDNs

·         Field-based care management personnel dedicated to IDNs

·         Internal groups supporting IDN initiatives

·         Organizational structures for all groups

·         Examples and descriptions of services and programs implemented in partnership with the IDN customer

·         Future IDN strategy for each company

PharmaForce International also produces a wide variety of syndicated studies, including:

 

  • “Competitive Benchmarking of Leading Pharmaceutical Companies’ Health Economics and Outcomes Research (HEOR) Initiatives: Field-based and Internal Scientific Groups.” Available December 15, 2012. Call or email now for pre-publication pricing
  • “The PharmaForce Global Sales Force Deployment Analyzer”, an “ever-green” online database which contains complete information on sales force sizes, product priorities and sales representative compensation packages at leading pharma companies in the United States, 10 countries in Europe, 3 countries in Latin America Japan and India.  To view a demonstration, go to http://www.deploymentanalyzer.com/ and click on the Demo login button
  •  “Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations in the United States, Europe, Japan and Latin America”
  • “Managed Markets Structures and Strategies: Leading Pharmaceutical Companies’ Approaches”
  • “Competitive Benchmarking of Leading Pharmaceuticals Companies’ Strategies for Leveraging the Medical Science Liaison Function in the United States”

 

Contact:  PharmaForce International Sales:  610-370-5640 or pfi@pharmaforce.biz

Top of page

'

10th Annual European Oncology Benchmarking Report
Release Date: 10/6/2012

10th Annual European Oncology Benchmarking Report:

PharmaForce International Announces Immediate
Availability

 

PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its 10th Annual Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations in Europe report.  This highly respected report reveals key expenditures and organizational approaches of 12 leading companies in the Big 5 European Union (EU) countries: France, Germany, Italy, Spain and the United Kingdom.

               

“Sales force deployment for oncology is always in flux,” said PharmaForce International’s Senior Director of International Operations Angelo Cupani. “In the past year, some companies have downsized, some grew, while others assimilated sales forces acquired through mergers or acquisitions. Additionally, multi-layer one-team approaches have been created by others.  Some new customer- and patient-facing positions in Medical Affairs and in Sales have been put in place, too,” added Senior Director of International Operations Anja Thiele Wiand. 

 

The 2012 report also adds another year of data into the historical trends analysis for each drug, showing sales force FTEs over the past five years, plus

 

  • Strategic overview
  • Sales force deployment
  • Organizational charts
  • Product portfolio management
  • Number of details by brand by target physician audience
  • Function of Medical Liaisons and Key Accounts Management personnel
  • Sales force compensation
  • Marketing expenditures by brand

“These five reports --- France, Germany, Italy, Spain and the United Kingdom --- are priced separately, but with significant combination discounts are available if a client purchases multiple geographic versions at once,” said EU Marketing Director Marija Jukic. “Samples of company profiles are available upon request.”

 

PharmaForce International also produces custom reports upon client request as well as syndicated studies, including:

 

  • The “Deployment Analyzer” which contains complete information on sales force sizes, product priorities and compensation for sales representatives at 25 companies across 10 EU countries.

 

  • Medical Liaisons in Europe: Competitive Benchmarking od Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaisons Function
  • Benchmarking of Leading Hepatitis C Sales and Marketing Organizations in Europe: Expenditures and Organizational Approaches – Due out in July 2012

 

 

For more information, contact Marija Jukic at + 387 (0) 30.830.043, Mobile: + 1-267-455*6649 Fax: +1 610.370.5641 or  mjukic@pharmaforce.biz

Top of page

'

5th Annual Latin America Oncology Benchmarking Report
Release Date: 10/1/2012

Contact:  Angelo Cupani, Senior Director of International Operations

 

5th Annual Latin America Oncology Benchmarking Report:

PharmaForce International Announces Immediate
Availability

 

For immediate release – October 2012.

 

PharmaForce International has announced the availability of its 5th Annual Benchmarking of Leading Oncology Sales and Marketing Organizations in Latin America report.  This comprehensive report reveals key expenditures and organizational approaches of 10 companies in 4 major Latin America countries: Argentina, Brazil, Mexico and Venezuela. .

This year we have expanded our offering by including historical trend analysis for each drug in each country showing sales force FTEs and marketing expenditure evolutions over the past 5 years. We have also added an ‘Industry Overviews Average Analysis’ section for each country illustrating averages and medians of deployment, target audiences, call reach and frequency, compensation and marketing expenditures based on company size and overall perspective. 

 

The 2012 report also adds another year of data that covers:

 

  • Strategic overview of each franchise
  • Key field force and marketing personnel
  • Organizational charts
  • Product portfolio management
  • Detailing intensity analysis
  • Call reach and frequency analysis
  • Role of Medical Liaisons
  • Sales force compensation
  • Marketing expenditures by brand and indication

Equivalent editions of the report are available for companies in the European Union (EU), Japan and the United States oncology markets.

 

These four reports --- US, Japan, the EU and Latin America --- are priced separately, but with significant combination discounts available if a client purchases multiple geographic versions at once.  Sample company profiles are available to prospective clients upon request.

 

PharmaForce International also produces custom reports at client request as well as syndicated studies, including:

 

  • The “Deployment Analyzer” covering sales force sizes, product priorities and compensation for sales representatives in the US, Europe, India, Japan, and Latin America . (To see a free demonstration, go to www.pharmaforcedeploymentanalyzer.com and click on the Demo login button.)
  • Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States --- 12th Annual Update” (May 2012)
  • Competitive Benchmarking of Leading Hepatitis Sales and Marketing Organizations in Europe and the United States”

 

For more information, contact Angelo Cupani at 610-370-1627 or at angelo.cupani@pharmaforce.biz

Top of page

'

8th Annual Japan Oncology Benchmarking Report
Release Date: 8/29/2012

Contact:  Greg Yoder, Director of Asia-Pacific Operations

 

8th Annual Japan Oncology Benchmarking Report:

PharmaForce International Announces Immediate Availability

 

For immediate release – August 29, 2012. PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the availability of its 8h Annual Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations report.  This comprehensive report reveals key expenditures and organizational approaches of 10 companies in Japan.  Equivalent editions of the report are available for companies in the United States (US), European Union (EU), and in the Latin American oncology markets.

               

“Sales force deployment for oncology in Japan continues to evolve,” said PharmaForce International’s Asia-Pacific Business Unit Director, Greg Yoder. “Multiple companies entered the generics market this year.  Additionally, we have seen several product launches and a few companies downsize after losing patent protection for their mainstay oncology products, forcing a change of direction in their detailing activities.  A few Japanese national companies have begun to more closely resemble western sales force structure and have created oncology specialty forces while others continue to promote oncology drugs along with products from multiple therapeutic areas.”

 

The 2012 report also adds another year of data into the historical trends analysis for each drug showing sales force FTEs and marketing expense evolution over the past five years, plus

 

·         Strategic overview

·         Sales force deployment

·         Organizational charts

·         Product portfolio management

·         Number of details by brand by target physician audience

·         Use of Medical Liaisons

·         Sales force compensation

·         Marketing expenditures by brand and indication

The four annual reports Pharmaforce produces for the oncology market  --- US, Japan, the EU and Latin America --- are priced as separate products but the company continues to offer significant combination discounts if clients wish to purchase the report in multiple geographic areas.  Sample companies from each geographic area are available to any prospective client who would like to see what the report has to offer.

 

PharmaForce International produces custom reports at client request as well as syndicated studies that include:

 

·         The “Deployment Analyzer” which contains complete information on sales force sizes, product priorities and compensation for sales representatives at more than 60 companies in the US, more than 25 companies each in Japan and the EU and 12 companies each in India and Latin America. (To see a demonstration, go to www.pharmaforcedeploymentanalyzer.com and click on the Demo login button.)

·         “Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States and Europe

·         “Key Accounts and National Healthcare Systems Managers in Europe: 10 Companies’ Approaches”

·         “Competitive Benchmarking of Leading Immunology/Anti-TNF Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches”

·         “Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Managed Markets”

 

For more information, contact Greg Yoder at 610-370-1377 or at gyoder@pharmaforce.biz

Top of page

'

12th Annual Benchmarking Report on the Medical Science Liaison
Release Date: 6/1/2012

12th Annual Benchmarking Report on the Medical Science Liaison Function immediately available from PharmaForce International

PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its 12th Annual Update of Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function.

“The accelerating trend of specialization within the field-based Medical Affairs liaison function has become more evident over the past year. Company after company has deployed specialty liaison groups that call on customers beyond the traditional KOL,” notes PharmaForce International Senior Vice President Sean McCrae. “There is hardly a company that has not realigned or expanded in some significant manner,” McCrae continued. “Some see all this change as turmoil, but we at PharmaForce International interpret it as healthy responses to changing company priorities as they decide where to deploy these valuable personnel.”

The primary research conducted by PharmaForce professionals provides insights and value far beyond the typical report which relies solely on secondary research. Many of the key insights in the report are as a result of in-depth conversations with knowledgeable company individuals. For example:

  • Learn which companies are….

       -         Developing role specialization with Health Outcomes Liaisons, Payer MSLs, Liaisons calling on NPs and PAs as well as those working exclusively with clinical trials

-         Deploying ‘reactive only’ vs. ‘proactive’ MSLs. Having tried a reactive approach, some companies have returned to a proactive stance while others have adopted a ‘reactive only’ policy

-         Increasing use of metrics to gauge MSL performance and measure effectiveness

 

PharmaForce International will send a sample company report from the 12th Annual Update of Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function to prospective clients who contact McCrae.

 PharmaForce International produces custom reports at client request as well as additional syndicated studies, including: 

  • The online and constantly refreshed “Deployment Analyzer” contains complete up-to-date information on sales force sizes, product priorities and compensation for sales representatives at over 60 companies in the US and 25 companies each in Japan and in Europe. For a demo, go to http://www.pharmaforcedeploymentanalyzer.com/ and click on the Demo Login button
  • “11th Annual Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations”
  • “Managed Markets Structures and Strategies: 10 Leading Companies Approaches”
  • “Medical Liaisons in Europe: 10 Leading Companies Approaches”

 For more information, contact Sean McCrae at 610-370-5640 or at smccrae@pharmaforce.biz

 

Top of page

'

11th Annual Oncology Benchmarking Report
Release Date: 5/11/2012

11th Annual Oncology Benchmarking Report:
PharmaForce International Announces Immediate Availability

PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its 11th Annual Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations report.  This highly respected report reveals key expenditures and organizational approaches of 18 companies in the United States.  Equivalent editions of the report are available for companies in the European Union (EU), Japan and in Latin American oncology markets.
 
“Sales force deployment for oncology is always in flux,” said PharmaForce International’s Senior Vice President Sean McCrae. “In the past year, some companies have downsized, some grew, while others assimilated sales forces acquired through mergers or purchase. Additionally, multi-layer one-team approaches have been created by others.  Some new customer- and patient-facing positions in Medical Affairs and in Sales have been put in place, too,” McCrae continued. 

The 2012 report also adds another year of data into the historical trends analysis for each drug, showing sales force FTEs and marketing expense evolution over the past five years, plus

• Strategic Overview
• Sales force deployment
• Organizational charts
• Product portfolio management
• Number of details by brand by target physician audience
• Use of Medical Liaisons
• Role of reimbursement personnel
• Sales force compensation
• Marketing expenditures by brand
“These four reports --- US, Japan, the EU and Latin America --- are priced separately, but with significant combination discounts available if a client purchases multiple geographic versions at once,” said McCrae.  “I will send a sample company profile to prospective clients who request one.”

PharmaForce International produces custom reports at client request as well as syndicated studies, including:

• The “Deployment Analyzer” which contains complete information on sales force sizes, product priorities and compensation for sales representatives at more than 60 companies in the US and more than 25 companies each in Japan, India, China and the EU. (To see a demonstration, go to www.pharmaforcedeploymentanalyzer.com and click on the Demo login button.)
• “Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function --- 12th Annual Update” (May 2012)
• “Key Accounts and National Healthcare Systems Managers in Europe: 10 Companies’ Approaches”
• “Competitive Benchmarking of Leading Immunology/Anti-TNF Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches”
• “Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Managed Markets”

For more information, contact Sean McCrae at 610-370-5640 or at smccrae@pharmaforce.biz

Top of page

'

2011

Second Annual Report on “Competitive Benchmarking of Leading Immunology/Anti-TNF Sales and Marketing Organizations in the United States
Release Date: 10/15/2011

Second Annual Report on “Competitive Benchmarking of Leading Immunology/Anti-TNF Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches” now available from PharmaForce International

PharmaForce International, the leader in pharmaceutical/biotech industry analysis, announces the immediate availability of its “Competitive Benchmarking of Leading Immunology/Anti-TNF Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches.”

“The immunology market is relatively mature but that does not mean it is standing still,” said Sean McCrae, PharmaForce International senior vice president. “Several companies have adjusted sales groups as well as marketing team staffing levels to meet current needs.  Additionally, our report provides up-to-date numbers for field-based Medical Affairs support personnel.”

The primary research conducted by PharmaForce professionals provides insights and value far beyond the typical report which relies solely on secondary research.  Many of the key insights in the report are as a result of in-depth conversations with knowledgeable company individuals.

For example, learn which companies have

  • Reduced, reallocated or eliminated sales representative coverage
  • Deployed third party Clinical Resource Nurses
  • Deployed Area Business Specialists
  • Added a drug from outside the inflammation category to the sales representatives promoted products responsibilities
  • Essentially stopped promoting in the Immunology space as corporate priorities shift to other therapeutic areas

PharmaForce International will send a sample company report from the “Competitive Benchmarking of Leading Immunology/Anti-TNF Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches” to prospective clients who contact McCrae.

PharmaForce International produces custom reports at client request as well as additional syndicated studies, including:

  • The online and constantly refreshed “Deployment Analyzer” contains complete up-to-date information on sales force sizes, product priorities, reach, frequency and compensation for sales representatives at 60 companies in the US and more than 25 companies each in Japan and in Europe. For a demo, go to www.pharmaforcedeploymentanalyzer.com and click on the Demo Login button
  • “Benchmarking Oncology Sales and Marketing Organizations in Europe, Japan, Latin America or the United States:  Key Expenditures and Organizational Approaches”
  • “Competitive Benchmarking of 15 Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States” 
  • Key Accounts and National Healthcare Systems Managers in Europe:  10 Companies’ Approaches

For more information, contact Sean McCrae at 610-370-5640 or at smccrae@pharmaforce.biz

Top of page

'

Competitive Benchmarking of Leading Multiple Sclerosis Sales and Marketing Organizations in the United States
Release Date: 10/15/2011

“Competitive Benchmarking of Leading Multiple Sclerosis Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches” available from PharmaForce International

 

PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its benchmarking report “Competitive Benchmarking of Leading Multiple Sclerosis Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches.” First-hand information gathered during one-on-one interviews with current employees of target companies fills the report.  This direct communication provided insights on how companies approach the Multiple Sclerosis market.

 

For each company in the report, see:

 

Field-Based Representatives

Expenditures for:

Organizational chart with headcount

Clinical trials

Products detailed / calls per month / FTEs

Advisory Boards

Salary and bonus ranges

Conventions

Marketing Department

Journal advertisements

Organizational chart with headcount

Patient programs

Field-based Medical Affairs

Advocacy groups

Organizational chart with headcount

Printed promotional sales materials

Salary and bonus ranges

Sales representative lunches/dinners

 

 

“Additionally, the report reveals any co-promotion agreements in place as well as the deployment of Certified Nurse Educators (CNEs) and Reimbursement Specialists, if applicable,” said Sean McCrae, PharmaForce International senior vice president.

 

PharmaForce International will send a sample report of one company along with the full list of companies contained in “Competitive Benchmarking of Leading Multiple Sclerosis Sales and Marketing Organizations in the United States: Key Expenditures and Organizational Approaches” to prospective clients who contact McCrae.

 

PharmaForce International produces custom reports at client request as well as syndicated studies, including:

 

  • The online and constantly refreshed “Deployment Analyzer” contains complete up-to-date information on sales force sizes, product priorities, reach, frequency and compensation for sales representatives at 60 companies in the US and more than 25 companies each in Japan and in Europe. For a demo, go to www.pharmaforcedeploymentanalyzer.com and click on the Demo Login button
  • “Benchmarking Oncology Sales and Marketing Organizations in Europe, Japan, Latin America or the United States: Key Expenditures and Organizational Approaches”
  • “Competitive Benchmarking of 15 Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States
  • Key Accounts and National Healthcare Systems Managers in Europe 10 Companies’ Approaches”

 

For more information, contact Sean McCrae at 610-370-5640 or at smccrae@pharmaforce.biz

Top of page

'

New benchmarking report on the Medical Science Liaison function in Europe
Release Date: 10/1/2011

Revealing new benchmarking report on the Medical Science Liaison function in Europe available now from PharmaForce International

PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its study Medical Liaisons in Europe: Competitive Benchmarking of Leading Companies’ Strategies for Leveraging the Function.

“The report provides expert analysis on the evolving importance of the Medical Science Liaison (MSL) function at 10 companies across the five major markets in Europe,” said Sean McCrae, PharmaForce International senior vice president. “For instance, in the UK our analysts have uncovered individual companies’ strategies to meet changes brought about by the proposed White Paper modifications to the NHS.”

McCrae  noted another example as well:  “In France, the same degree of detail is provided on companies’ responses to new guidelines that strengthen the regulatory firewall between field-based medical-affairs personnel and promotional sales forces.”

The primary research conducted by PharmaForce professionals provides insights and value far beyond the typical report which relies solely on secondary research.  Many of the key insights in the report are the results of in-depth conversations with knowledgeable target-company employees.

•         Among other key findings, customers will learn which companies are
?         committed to deploying increased numbers of MSLs
?         taking steps to expand and strengthen the MSL role
?         adjusting MSL compensation levels to better reflect the requirements of the role

PharmaForce International will send a sample company report from Medical Liaisons in Europe:  Competitive Benchmarking of Leading Companies’ Strategies for Leveraging the Function to prospective clients who contact McCrae.

PharmaForce International produces custom reports at client request as well as syndicated studies including:

• The online and constantly refreshed “Deployment Analyzer” contains complete up-to-date information on sales force sizes, product priorities, reach, frequency and compensation for sales representatives at 60 companies in the US and more than 25 companies each in Japan and in Europe. For a demo, go to www.pharmaforcedeploymentanalyzer.com and click on the Demo Login button.
• “Benchmarking Oncology Sales and Marketing Organizations in Europe, Japan, Latin America or the United States:  Key Expenditures and Organizational Approaches.”
• “Competitive Benchmarking of 15 Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States.”
• “Key Accounts and National Healthcare Systems Managers in Europe:  10 Companies’ Approaches.”

For more information, contact Sean McCrae at 1-610-370-5640 or at smccrae@pharmaforce.biz

 

Top of page

'

2010

PharmaForce International Deployment Analyzer Upgraded
Release Date: 8/28/2010

PharmaForce International Deployment Analyzer Upgraded

PharmaForce International continues to update and improve its web-based Deployment Analyzer, an essential tool for pharmaceutical/biotech sales and marketing managers.  The Deployment Analyzer contains complete information on nearly 50 pharmaceutical/biotech sales force sizes, their product priorities and compensation.

PharmaForce is a recognized leader that decision makers in the industry depend on to maintain their competitive edge.  PharmaForce remains a known constant in these turbulent times with an experienced, knowledgeable, international workforce committed to meeting clients’ needs. 

“Our Web-based Deployment Analyzer is constantly updated.  This feature is especially valuable at this point in time as almost all pharmaceutical/biotech sales forces are being reorganized and resized,” said Sean McCrae, Senior Vice President of Sales at PharmaForce International.  “Companies seem to be performing these adjustments either in planned stages or in reactive response to evolving market conditions, with some companies having made multiple adjustments in the past year.  Lately, it seems that every week, we adjust the online database for at least one company.” 

PharmaForce International positions the Deployment Analyzer as the logical alternative to any printed report which becomes outdated almost immediately after it is released.

“Our pharmaceutical and biotech clients value the evergreen aspect of the Deployment Analyzer, knowing that they can confidently base their decisions on data that is accurate and virtually up to the minute,” McCrae said.  “In addition to the U.S. version, we also offer a version covering 25 sales forces in Japan and a European version covering 25 companies in 10 different countries.”

To see a demonstration of PharmaForce International’s Deployment Analyzer, go to http://pharmaforcedeploymentanalyzer.com and click on the Demo login button.

Along with the Deployment Analyzer, PharmaForce International conducts multiple versions of competitive intelligence studies, producing custom reports at client request as well as producing syndicated studies including:

  • Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations in the United States, Europe, Latin America and Japan: Key Expenditures and Organizational Approaches
  • Competitive Benchmarking of 15 Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States
  • Competitive Benchmarking of Key Opinion Leader Relationship Management by Leading Pharmaceutical and Biotech Companies in the United States
  • Competitive Benchmarking of 10 Leading Pharmaceutical Companies’ Strategies for Managed Markets
  • Key Opinion Leader Perspectives on World Class Advisory Boards in Europe
  • Key Opinion Leader Perspectives on World Class Advisory Boards in the United States
  • Competitive Benchmarking of Patient Compliance, Adherence and Persistence Departments and Strategies of Leading Pharmaceutical Companies

For more information, contact Sean McCrae at 610-370-5640 or at smccrae@pharmaforce.biz

Top of page

'

2009

Medical Science Liaisons - Function Continues to Evolve
Release Date: 7/14/2009

Top of page

'

9th Annual Benchmarking Report on the Medical Science Liaison
Release Date: 7/8/2009

PharmaForce Int’l Announces Immediate Availability of its 9th Annual Benchmarking Report on the Medical Science Liaison Function

 PharmaForce International, the leader in pharmaceutical/biotech industry analysis, has announced the immediate availability of its 9th Annual Update of Competitive Benchmarking of Leading Pharmaceutical Companies’ Strategies for Leveraging the Medical Liaison Function in the United States.

 

“It seems that while companies are downsizing their field sales representative presence, they are increasing the responsibilities and expected contributions of their Medical Science Liaison (MSL) groups,” said PharmaForce Senior Vice President Sean McCrae who was recently quoted in the Wall Street Journal regarding the role of the MSL.

 

The report also demonstrates many companies are increasing emphasis on the number of MSL calls on and interactions with assigned key opinion leaders.

 

“The value of our MSL report has been enhanced this year with a substantial retrospective analysis of key data points from past reports”, said McCrae. “We have a lot of great historical data, the value of which has been unlocked in the 2009 report. Rather than offering the MSL report as a snapshot in time as we have in the past, it now provides information about how the data points have evolved over several years.”

 

The in-depth interviews with pharmaceutical/biotech medical affairs personnel reveal interesting new applications for deploying, directing and supporting the MSL asset, most notably

 

  • MSLs are employed as a key asset to support high-priority managed-care strategies.
  • Dedicated internal medical affairs positions are created to liaise with the commercial side.
  • Dedicated MSL trainers standardize and document skills of the MSL.

 

PharmaForce will send a sample company report to prospective clients who contact McCrae. (Information supplied below.)

 

PharmaForce International produces custom reports at client request as well as additional syndicated studies, including:

 

  • The “Deployment Analyzer,” a Web-based tool that contains complete information on sales force sizes, product priorities and compensation for sales representatives at more than 50 companies in the US and more than 25 companies each in Japan and in Europe. To see a demonstration, go to http://www.pharmaforcedeploymentanalyzer.com/ and click on the Demo login button.
  • The 2009 PhRMA Code Revisions: Benchmarking of Leading Pharmaceutical Companies’ Approaches and Responses.
  • Competitive Benchmarking of Leading Oncology Sales and Marketing Organizations in the United States, Europe, Latin America and Japan: Key Expenditures and Organizational Approaches.
  • Competitive Benchmarking of 10 Leading Pharmaceutical Companies’ Strategies for Managed Markets (August 2009: call for pre-publication price).
  • Competitive Benchmarking of Patient Compliance, Adherence and Persistence Departments and Strategies of Leading Pharmaceutical Companies.
  • On-Site Medical Convention Coverage (call for a specific quote).
  • Key Opinion Leader Perspectives on World Class Advisory Boards (U.S. and Europe reports).

 

For more information, contact Sean McCrae at 610-370-5640 or at smccrae@pharmaforce.biz

Top of page

'

Study Benchmarks How Companies are Interpreting the New PhRMA Code
Release Date: 6/17/2009

Top of page

'

PharmaForce International Releases New Oncology Study
Release Date: 6/4/2009

Top of page

'

Deployment Tool Tracks 92 Percent of All U.S. Pharmaceutical Sales Forces
Release Date: 4/8/2009

Top of page

'

2008

The managed markets arena – a study in success
Release Date: 4/23/2008

Top of page

'

Advisory boards -- Catalysts to a better bottom line
Release Date: 4/10/2008

Top of page

'
                              PharmaForce International Inc.
                              UNITED STATES - BOSNIA - COLOMBIA -
INDIA - JAPAN - NETHERLANDS - UNITED KINGDOM
                              2645 Perkiomen Avenue • Reading, PA 19606 • (610) 370-5640 • Fax (610) 370-5641 • www.pharmaforce.biz
| Sitemap

Apycom jQuery Menus